ArticleBritish journal of pharmacology2003
Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor.
Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Structural basis for receptor selectivity and inverse agonism in S1PNature communications · 2022Article
- PTEN regulates natural killer cell trafficking in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier.Journal of neuroinflammation · 2012Article
- T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.Leukemia & lymphoma · 2011Review
- Targeting sphingosine-1-phosphate receptors in cancer.Anti-cancer agents in medicinal chemistry · 2011Review
- Effect of S1P5 on proliferation and migration of human esophageal cancer cells.World journal of gastroenterology · 2010Article
- Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.The American journal of pathology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1 We tested the hypothesis, whether G Protein-coupled receptors (GPCRs) may differentially regulate specific signalling pathways by constitutive and agonist-induced activation using the human sphingosine 1-phosphate receptor S1P(5) as a model. 2 S1P(5) receptor-expressing HEK293 cells exhibited a high degree of basal activity for both inhibition of adenylyl cyclase and extracellular signal regulated kinase (ERK) when cultured in serum, which contains high levels of sphingosine 1-phosphate (S1P). However, basal activity was independent of the presence of S1P: (i) constitutive activity remained when cells were cultured in delipidated serum, (ii) addition of S1P to delipidated serum did not increase basal S1P(5) receptor signalling. 3 Conversely, constitutive inhibition of forskolin-stimulated adenylyl cyclase was further enhanced by S1P in S1P(5)-HEK293 cells. 4 Transfection of several mammalian cell lines (CHO-K1, HEK293, NIH-3T3, RH7777) with the S1P(5) receptor induced cell rounding, which was more pronounced in the presence of S1P-containing serum. Rounded cell morphology did not correlate with apoptotic cell death, but led to detachment of cells. 5 Cell surface ELISA assays showed that a fraction of plasma membrane S1P(5) receptors were dose-dependently internalized with S1P. 6 These data reveal that intrinsic inhibition of unstimulated adenylyl cyclase or ERK activity by the S1P(5) receptor is insensitive to ligand modulation. Conversely, effects on forskolin-stimulated adenylyl cyclase, cell morphology and internalization can be further augmented with S1P. Our results suggest that different signal transduction pathways are not equally activated through constitutively active GPCRs with promiscuous signalling characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.